ALERTS-drug safety updates
Drug safety updates from MHRA
Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido Cases of sexual dysfunction, predominantly involving erectile dysfunction and decreased libido, have been reported rarely in patients taking oral isotretinoin for severe acne. Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows’ milk allergySolu-Medrone 40 mg may contain trace amounts of milk proteins. Gabapentin (Neurontin): risk of severe respiratory depressionGabapentin has been associated with a rare risk of severe respiratory depression even without concomitant opioid medicines. https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libidoCases of sexual dysfunction, predominantly involving erectile dysfunction and decreased libido, have been reported rarely in patients taking oral isotretinoin for severe acne. Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileusIf constipation occurs during treatment with clozapine (Clozaril, Denzapine, Zaponex), it is vital that it is recognised and actively treated. Letters sent to healthcare professionals in September 2017Letters were sent in September about Dacogen (decitabine), Eperzanâ–¼(albiglutide), ERWINASE, ReoPro (abciximab), and recombinant human erythropoietins. https://www.gov.uk/drug-safety-update/letters-sent-to-healthcare-professionals-in-september-2017 Medical Device Alerts issued in September 2017Alerts were recently issued about Accu-Chek insulin pumps, Astral lung ventilators, and IntelliVue patient monitors used with 12-lead ECG. https://www.gov.uk/drug-safety-update/medical-device-alerts-issued-in-september-2017 Drug Safety Update is a monthly newsletter from the Medicines and Healthcare products Regulatory Agency (MHRA) and its independent advisor the Commission on Human Medicines. Enquiries about this email should be sent to: email.support@mhra.gsi.gov.uk. |
